MEDIA & PRESS UPDATES

Glaukos Announces Global Licensing Agreement Amendment

with Intratus, Inc. to Include the Treatment of Presbyopia

Amendment Adds Presbyopia as a New Investigational Application for Patented,

Non-Invasive, Topical Eyelid Drug Delivery Platform 

Presbyopia Expands Upon Already Established Investigational Applications for

Dry Eye Disease, Glaucoma and Other Corneal Disorders

April 22, 2021 07:00 AM (EDT)

SAN CLEMENTE, Calif. -- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into an amended licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform (the Eyelid Drug Delivery Platform) for application in the treatment of presbyopia.

The addition of presbyopia expands upon the existing agreement between the two parties announced on July 22, 2019, under which Glaukos secured a global exclusive license to research, develop, manufacture and commercialize the Eyelid Drug Delivery Platform for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions. Additionally, the amendment includes a mechanism to further expand the existing agreement to other indications, applying the active pharmaceutical ingredients being advanced by Glaukos in glaucoma, corneal disorders and presbyopia to new ophthalmic fields.

“We are excited to expand our partnership with Intratus by adding presbyopia as a new investigational application for this novel drug delivery platform and build upon the promising R&D work we’ve completed thus far in dry eye disease, glaucoma and other corneal disorders,” said Thomas Burns, Glaukos president and chief executive officer. “The Eyelid Drug Delivery Platform uses a differentiated, non-invasive, patient-friendly, transdermal approach and is highly complementary to our expanding portfolio of sustained pharmaceutical platforms in glaucoma, corneal health and retinal disease.”

“Intratus is pleased to have our platform technology continue its expansion through a second license with Glaukos,” said Aaron Dyer, Intratus president and chief executive officer. “We look forward to the progress Glaukos will continue to make and ultimately the restoration of sight we hope to provide for patients.”

Presbyopia is a natural part of aging due to the hardening of the eye’s crystalline lens over time, resulting in a loss of lens elasticity or the ability of the lens to change shape in order to focus incoming light on the retina. With this loss of flexibility, eyes are less able to adjust properly to focus on near objects. Presbyopia usually becomes noticeable around the age of 40 and there is no proven way to stop or reverse the progression of presbyopia.

The Eyelid Drug Delivery Platform’s patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops.

Under the expanded agreement, Glaukos will obtain an exclusive global license to Intratus’ drug delivery technology for use in the treatment of presbyopia, in addition to glaucoma and corneal disorders, including dry eye disease, allergy, blepharitis, conjunctivitis and related conditions. Financial terms of the agreement were not disclosed.

About Intratus, Inc.

Intratus, Inc. is a privately held, clinical-stage life sciences company dedicated to the development of its patented, novel, non-invasive drug delivery platform technologies focused on the treatment of ophthalmic diseases. Intratus is headquartered in San Diego, California.

About Glaukos 

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Glaukos Announces Global Licensing Agreement With Intratus, Inc.

July 22, 2019

Novel, Non-Invasive Drug Delivery Platform Expands Glaukos’ Portfolio of Sustained Pharmaceutical Systems

Includes Lead Candidate for Treatment of Dry Eye Disease with Potential Future Candidates for Other Corneal Disorders and Glaucoma

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.

Intratus’ patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops.

“This licensing agreement adds a novel drug delivery platform using a differentiated, non-invasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” said Thomas Burns, Glaukos president and chief executive officer. “Intratus’ proprietary transdermal drug delivery application is highly complementary to our expanding portfolio of sustained pharmaceutical systems and represents a synergistic fit with our glaucoma and corneal health R&D initiatives. With this agreement, we plan to build upon the promising development work Intratus has completed to advance this exciting new drug delivery approach into the appropriate clinical phases.”

“Intratus’ drug delivery platforms aim to provide an efficacious, safe and durable treatment option for ophthalmic diseases through a simple, non-invasive and patient-friendly method of application,” said Aaron Dyer, co-founder and chief executive officer, and Padma Nanduri, M.D. FACS, co-founder and chief medical officer. “We believe Glaukos’ proven track record in pioneering new treatment paradigms makes them the perfect partner to help bring our novel treatment options, if approved, to patients and physicians in the most effective and timely manner possible.”

Under the agreement, Glaukos will obtain an exclusive global license to Intratus’ drug delivery technology for use in the treatment of glaucoma and corneal disorders, including dry eye disease, allergy, blepharitis, conjunctivitis and related conditions. Financial terms of the agreement were not disclosed.

About Intratus, Inc.

Intratus, Inc. is a privately held life sciences company dedicated to utilizing its patented novel drug delivery platform technologies for the treatment of ophthalmic diseases and disorders. Intratus is headquartered in San Diego, California.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease